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prognostic value of peak oxygen consumption (VO2) in heart
failure (HF) patients (1). Lavie and colleagues present an
interesting theory that the superior survival in female HF
patients may be due to their higher body fat content. Although
a plausible assumption at first glance, we controlled for several
important variables in our study population to account for body
fat composition. First, body mass index (BMI), a reliable
surrogate for body fat content (2), was equivalent between
genders in our study. Regardless of this, to address Lavie’s
concerns, we reanalyzed our data to correct for body composi-
tion. As skin-fold measurements were not performed on our
patients, we adjusted peak VO2 values to “ideal body weight,” as
calculated using the Wasserman formulae (3). We found that
the gender difference in peak VO2 persisted: peak VO2/ideal
body weight  16.5  5.7 ml/kg/min in women and 18.7  7.9
ml/kg/min in men (p  0.002). Thus, higher percent body fat
does not explain the lower peak VO2 or improved survival in
female HF patients.
Although Dr. Lavie and colleagues speculate that the difference
in body fat composition accounts for the gender differences in
exercise capacity in HF patients, it is clear that the mechanisms for
gender differences are much more complex. For example, myocar-
dium responds differently between the genders to stresses such as
increased afterload (4–6), and data suggest that this may be due to
hormonal influences on regulation of vasculature and myocardial
responses (6,7). Additionally, sudden cardiac death, which ac-
counts for approximately 40% of HF deaths, occurs less frequently
in women, potentially explaining their prolonged survival (8).
Given the complex HF pathophysiology, multiple factors are likely
responsible for the observed gender difference beyond just body fat
composition. We hope our study will encourage additional re-
search into the mechanism of gender differences in HF so that the
best treatment decisions can be made and the best therapies can be
applied to all patients.
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Atrial Fibrillation and Clinical
Events in Chronic Heart Failure
The study by Olsson et al. (1) found that atrial fibrillation (AF) is
associated with a worse outcome in patients with heart failure
(HF) regardless of whether HF is associated with depressed or
relatively preserved ventricular function, although those with
preserved left ventricular (LV) function had better survival than
did those with depressed LV function. In a series of 478 patients
hospitalized with AF and HF we observed that those with
preserved LV function had a similarly poor prognosis as did those
with depressed LV function when adjusted for age, gender,
coronary artery disease, and comorbid illness (2).
Differences in these findings might be illuminating. Whereas
the CHARM (Candesartan in Heart failure-Assessment of Re-
duction in mortality and morbidity) program enrolled stable HF
patients, our study population were patients who had a deteriora-
tion necessitating hospitalization. We observed a steep increase in
mortality shortly after the index hospitalization, suggesting that
such an event is a potent marker for mortality warranting aggres-
sive management. We also found an association between decreased
mortality and statin therapy, intriguing in view of recent speculation
that inflammation and fibrosis may be involved in promoting AF. It
would be of interest to know whether intercurrent development of AF
had a different prognosis as compared to pre-existing AF in CHARM
and whether statin therapy disproportionately affects outcomes.
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Reply
Drs. Parkash and Stevenson relate that in their experiences the
survival of patients with both atrial fibrillation (AF) and heart
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failure (HF) was similarly impaired whether the ejection fraction
was depressed or preserved in patients hospitalized for HF. Of
interest, although in the CHARM (Candesartan in Heart failure-
Assessment of Reduction in mortality and morbidity) study there
was an overall better survival in those patients with preserved
ejection fraction (1), the presence of AF in those patients had a
greater negative impact (2), raising the suggestion that AF tends to
equalize the risk in patients with low compared with preserved
ejection fractions. There was an increased risk with new-onset AF,
and patients with low ejection fraction had the worst prognosis,
but we could not assess the time-dependence of this risk. We have
previously reported the time-dependent relationship with new-
onset AF and subsequent increased risk in another patient popu-
lation with chronic heart failure (3).
Parkash and Stevenson also raise the intriguing possibility that
an anti-inflammatory action of a statin in patients with both AF
and HF may improve outcome. In CHARM, the results were
adjusted for baseline variables but not for baseline concomitant
treatment, as causality and selection bias for treatments are
impossible to distinguish in such a trial (4).
The ongoing CORONA (Controlled Rosuvastatin Multina-
tional Study in Heart Failure) trial has randomized patients
with symptomatic HF to either placebo or rosuvastatin (5).
Because 24% of the enrolled patients have AF at baseline and
more will develop AF during the study, analysis of this
randomized trial data will undoubtedly provide more definitive
information regarding the effects of a statin in patients with
both AF and HF.
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